Literature DB >> 35766077

Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study.

Simone Amabile, Luca Tonella, Marco Rubatto, Giuseppe Argenziano, Graziella Babino, Pasquale Frascione, Emi Dika, Luca Giacomelli, Aurora Parodi, Pietro Quaglino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35766077      PMCID： PMC9170549          DOI： 10.1684/ejd.2022.4198

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   2.805


× No keyword cloud information.
  9 in total

1.  Multicentre comparison of skin hydration in terms of physical-, physiological- and product-dependent parameters by the capacitive method (Corneometer CM 825).

Authors:  U Heinrich; U Koop; M-C Leneveu-Duchemin; K Osterrieder; S Bielfeldt; C Chkarnat; J Degwert; D Häntschel; S Jaspers; H-P Nissen; M Rohr; G Schneider; H Tronnier
Journal:  Int J Cosmet Sci       Date:  2003-04       Impact factor: 2.970

2.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

Review 3.  Incidence and risk of xerosis with targeted anticancer therapies.

Authors:  Johannah Valentine; Viswanath Reddy Belum; Juanita Duran; Kathryn Ciccolini; Katja Schindler; Shenhong Wu; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2015-01-27       Impact factor: 11.527

Review 4.  Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.

Authors:  Jennifer Nam Choi
Journal:  Semin Cutan Med Surg       Date:  2014-03

5.  EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: clinical scoring systems.

Authors:  J Serup
Journal:  Skin Res Technol       Date:  1995-08       Impact factor: 2.365

6.  Tape-stripping method in man: comparison of evaporimetric methods.

Authors:  Hongbo Zhai; Emi Dika; Marina Goldovsky; Howard I Maibach
Journal:  Skin Res Technol       Date:  2007-05       Impact factor: 2.365

Review 7.  Cutaneous Complications of Targeted Melanoma Therapy.

Authors:  Emily de Golian; Bernice Y Kwong; Susan M Swetter; Silvina B Pugliese
Journal:  Curr Treat Options Oncol       Date:  2016-11

8.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Authors:  Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

9.  Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Authors:  Paolo A Ascierto; Reinhard Dummer; Helen J Gogas; Keith T Flaherty; Ana Arance; Mario Mandala; Gabriella Liszkay; Claus Garbe; Dirk Schadendorf; Ivana Krajsova; Ralf Gutzmer; Jan Willem B de Groot; Carmen Loquai; Ashwin Gollerkeri; Michael D Pickard; Caroline Robert
Journal:  Eur J Cancer       Date:  2020-01-02       Impact factor: 9.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.